EA
CRDF icon

Emerald Advisers’s Cardiff Oncology CRDF Stock Holding History

Emerald Advisers’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-214,376
Closed -$3.86M – 259
2020
Q4 		$3.86M Sell
214,376
-144,959
-40% -$2.55M 0.13% 124
2020
Q3 		$5.1M Buy
+359,335
New +$2.37M 0.21% 110

Other funds holding CRDF

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Emerald Advisers's CRDF Position: Q1 2021 in Review

Emerald Advisers sold out of Cardiff Oncology (CRDF) in Q1 2021, closing a stake of 214,376 shares — an estimated $3.86M sold.

Emerald Advisers first reported a position in CRDF in Q3 2020 and held it in 2 quarters. The position peaked at $5.1M in Q3 2020. 73 funds tracked by Wall St. Rank hold CRDF as of Q1 2021.

  • Emerald Advisers reported no remaining Cardiff Oncology position as of Q1 2021 after selling out during the quarter.
  • Emerald Advisers sold 214,376 Cardiff Oncology shares in Q1 2021, an estimated $3.86M.
  • Emerald Advisers first reported a position in Cardiff Oncology in Q3 2020 and held it in 2 quarters.
  • Emerald Advisers's Cardiff Oncology position peaked at $5.1M in Q3 2020.
  • 73 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2021.

Based on Emerald Advisers's 13F filing for Q1 2021, filed 29 Apr 2021.